# Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer

Source: https://onco.cc/trials/nct05132075/  
OnCo record `nct05132075` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial testing JDQ443 in non-small-cell lung cancer, active and no longer recruiting.

## Summary

Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer is a phase 3 interventional study registered as NCT05132075, led by Novartis Pharmaceuticals, and active but no longer recruiting on the registry. Official title: A Randomised, Controlled, Open Label, Phase III Study Evaluating the Efficacy and Safety of JDQ443 Versus Docetaxel in Previously Treated Subjects With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer. Planned enrolment is 95 participants (actual). The study started in 2022-06-15 and primary completion is expected in 2026-08-25. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-11
- Also known as: KontRASt-02
- Tags: ctgov-ingest
- Registry id: NCT05132075
- Phase: 3
- Setting: A Randomized, Controlled, Open Label, Phase III Study Evaluating the Efficacy and Safety of JDQ443 Versus Docetaxel in Previously Treated Subjects With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer
- Sponsor: Novartis Pharmaceuticals
- Enrolled: 95

## Sources

- ClinicalTrials.gov NCT05132075: https://clinicaltrials.gov/study/NCT05132075

## Connected records

- cancers: [KRAS G12C-mutant non-small-cell lung cancer](https://onco.cc/cancers/kras-g12c-nsclc/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [JDQ443](https://onco.cc/drugs/jdq443/)
- companies: [Novartis](https://onco.cc/companies/novartis/)

---
JSON: https://onco.cc/api/v1/entities/nct05132075.json